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Abstract
Background: It is important to evaluate the curability of and avoid unnecessary exploratory surgery for gastric
cancer preoperatively. However, no related research has been reported until now. The aim of this study was to
evaluate the factors influencing surgery for incurable gastric cancer.
Methods: 310 cases of T3–4 gastric cancer patients were analyzed retrospectively, including 141 cases with radical
surgery and 169 with surgery for incurable gastric cancer. The incurable factors were categorized as T status
(unresectable T4 tumor), N status (unresectable lymph node), peritoneal metastasis, and distant metastasis. χ2 test
and logistic regression were performed to analyze the associations between curability, T status, N status, peritoneal
metastasis, or distant metastasis and clinicopathological data.
Results: Esophageal involvement and T grade were associated with curability. Cardia involvement and Borrmann
type were associated with T status. Esophageal involvement and T grade were associated with N status. Gastric
body involvement, esophageal involvement, and T grade were associated with peritoneal metastasis. Gastric antrum
involvement was associated with distant metastasis.
Conclusions: The influencing factors of surgery for incurable gastric cancer should be analyzed preoperatively.
Resectability should be evaluated according to these influencing factors combined with imaging analysis.
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Background
Gastric cancer is one of the most frequently diagnosed
cancers worldwide. According to GLOBOCAN 2012,
952,000 new cases of gastric cancer were estimated to
have occurred in 2012 (6.8 % of the total cancer burden)
and gastric cancer ranks fifth among most common ma-
lignancies. Approximately 24 % of gastric cancer cases
occurred in China [1], and the disease is the second
most common cancer in China [2, 3]. Gastric cancer is
the third leading cause of cancer-related death globally.
Over 95 % of cases have an adenocarcinoma histology,
and the disease is often diagnosed at an advanced stage.
The prognosis of gastric cancer has improved with ad-
vances in surgical techniques, chemoradiotherapy, and
molecular targeted therapy [4]. However, the long-term
outcomes of patients with gastric cancer remain poor,
particularly for those with advanced disease. The 5-year
survival rate in patients with early gastric cancer is 85–
100 %, while it is only 5–20 % for advanced gastric can-
cer patients. Surgery is still the cornerstone of gastric
cancer treatment, and locoregional control is important
[5]. However, the R0 resection rate for gastric cancer is
only 66.7 % with surgery alone [6]. There is no benefit
for patients with incurable disease to undergo surgical
treatment. Therefore, it is important to evaluate the cur-
ability of and avoid unnecessary exploratory surgery for
gastric cancer preoperatively. However, no related re-
search has been reported until now.
In our study, the clinicopathological data for gastric
cancer for surgery were reviewed. The associations be-
tween these clinicopathological factors and curability of
gastric cancer were analyzed. Simultaneously, the incur-
able factors were classified as T status (unresectable T4
tumor), N status (unresectable lymph node), peritoneal
metastasis, and distant metastasis. The related clinico-
pathological factors for each incurable factor were* Correspondence: jessie1217@hotmail.com3Department of Biochemistry, Institute of Basic Medical Science, Zhejiang
Medical College, Hangzhou 310053, People’s Republic of China
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analyzed. This study could provide a reference for the
curability evaluation of gastric cancer.
Methods
Patients
A total of 1961 cases of primary gastric cancer were
treated by surgery at Zhejiang Cancer Hospital
(Hangzhou, China) from January 2007 to December
2009. Among them, 1790 cases (91.3 %) received cura-
tive resection, which was defined as absence of tumor
macroscopically after operation. One hundred seventy-
one cases (8.7 %) were incurable (45 cases underwent
palliative resection, and 126 cases underwent exploratory
or bypass surgery). Two cases were excluded from the
171 incurable cases, because they had other cancers sim-
ultaneously. Therefore, 169 incurable cases were ana-
lyzed. All of the incurable cases were grades T3–4.
Meanwhile, 141 cases with pathological T3–4 stages
who underwent radical surgery from January 2007 to
August 2007 were chosen as the control group. All cases
had undergone both computed tomography (CT) and
endoscopy preoperatively. Cases with other cancers sim-
ultaneously were excluded from this research.
Data collection
The clinicopathological data (gender, age, surgery prop-
erties, tumor region, esophageal involvement, duodenal
involvement, Borrmann type, pathologic type, grading of
gastric cancer, and T grade) of all gastric cancer cases
with surgery for incurable disease and those with radical
surgery were collected. However, not all cases had data
for the Borrmann type or grading of gastric cancer. The
Borrmann type data were complete in 223 cases, and the
grading data were complete in 262 cases.
The tumor staging was determined according to the
2002 American Joint Committee on Cancer (AJCC). The
TNM stage system and T grade were applied according
to WHO guidelines. Pathological T was used in radical
or palliative resection cases. For those cases who had
undergone exploratory or bypass surgery, pathological
T was impossible; therefore, surgical staging was used.
The presence or absence of lymph node metastasis
was evaluated according to the tumor node metastasis
classification based on the postoperative histopatho-
logic examination. Incurable factors were categorized
as T status (unresectable T4 tumor), N status (unre-
sectable lymph node), peritoneal metastasis, and distant
metastasis.
Statistical analysis
Statistical analyses were performed using SPSS 16.0
(SPSS Inc., Chicago, IL, USA). The statistical analyses
were as follows:
Step 1: The associations between curability, T status, N
status, peritoneal metastasis, or distant metastasis and
clinicopathological data were analyzed by chi-square
test.
Step 2: Binary logistic regression (backward: condi-
tional method) was performed using curability, T status,
N status, peritoneal metastasis, and distant metastasis as
dependent variables and the related clinicopathological
data from step 1 (except Borrmann type and grading) as
covariates, because some cases had no available Borr-
mann type or grading data.
Step 3: If Borrmann type or grading factor was the re-
lated factor, binary logistic regression was then per-
formed again using curability, T status, N status,
peritoneal metastasis, or distant metastasis as dependent
variables and the related clinicopathological data from
step 2 plus Borrmann type or grading as covariates in
those cases with complete Borrmann type or grading
factor.
Step 4: If Borrmann type or grading factor was not the
related factor by binary logistic regression from step 3,
the results in step 2 were the final result. However, if
Borrmann type or grading factor was the related factor,
the results in step 3 were the final result.
Results
Patient characteristics
310 cases of gastric cancer were included in our study.
Of these cases, 141 underwent radical surgery and 169
cases underwent surgery for incurable disease (44 cases
underwent palliative resection, and 125 cases underwent
exploratory or bypass surgery). The mean age was 58.49
± 10.28 years (range 29 to 61 years) in the radical sur-
gery group and 56.75 ± 11.57 years (range 27 to 77 years)
in the incurable surgery group (p = 0.167). The radical
surgery group consisted of 106 male cases (75.2 %) and
35 female cases (24.8 %), and the incurable surgery
group consisted of 120 male cases (71.0 %) and 49 fe-
male cases (29.0 %) (p = 0.411). One or more factors
existed in each incurable case. They were categorized as
T status in 97 cases, N status in 53 cases, peritoneal me-
tastasis in 103 cases, and distant metastasis in 19 cases
(hepatic metastasis in 17 cases, supraclavicular lymph
node metastasis in 2 cases). Borrmann type data were
complete in 223 cases, and grading data were complete
in 262 cases.
Associations between curability, T status, N status,
peritoneal metastasis, or distant metastasis and
clinicopathological factors
Gender, age, surgical properties, tumor region, esopha-
geal involvement, duodenal involvement, pathologic
type, and T grade were analyzed in 310 cases, Borrmann
type was analyzed in 223 cases, and the grading of
Zhao et al. World Journal of Surgical Oncology  (2015) 13:339 Page 2 of 8
gastric cancer was analyzed in 262 cases. The results
showed that cardia involvement, gastric antrum involve-
ment, esophageal involvement, T grade, Borrmann type,
and grading of gastric cancer were associated with cur-
ability in univariate analysis by chi-square test (Table 1).
Cardia involvement, gastric antrum involvement,
esophageal involvement, duodenal involvement, T grade,
N status, peritoneal metastasis, and Borrmann type were
associated with T status. Cardia involvement, esophageal
involvement, T grade, and Borrmann type were associ-
ated with N status (Table 2). Age, gastric body involve-
ment, the number of regions, esophageal involvement,
signet ring cell carcinoma, T grade, Borrmann type, and
grading were associated with peritoneal metastasis. Gas-
tric antrum involvement was associated with distant me-
tastasis. The number of regions was nearly related to
distant metastasis (Table 3).
Multivariate analyses for curability, T status, N status,
peritoneal metastasis, and distant metastasis
Esophageal involvement and T grade were associated
with curability in 310 cases in multivariate analysis by
logistic regression. Next, the relationships of Borrmann
type, esophageal involvement, and T grade with curabil-
ity were analyzed in 223 cases by logistic regression. The
relationship between grading, esophageal involvement,
or T grade with incurable factors was analyzed in 223
cases by logistic regression. The results showed that
both esophageal involvement and the T grade were asso-
ciated with curability (Table 4).
Cardia involvement and duodenal involvement were
nearly related to the T status in 310 cases in multivariate
analysis by logistic regression. Next, the relationships of
Borrmann type, cardia involvement, and duodenal in-
volvement with incurable factors were analyzed in 223
Table 1 Associations between curability and clinicopathological data
Curability (n = 310)
Yes No p
Gender Male 106 120 0.411
Female 35 49
Age <60 years 72 96 0.312
≥60 years 69 73
Cardia Not involved 86 143 0.000**
Involved 55 26
Gastric body Not involved 65 75 0.762
Involved 76 94
Gastric antrum Not involved 72 51 0.000**
Involved 69 118
Number of regions 1 84 106 0.355
2 55 57
3 2 6
Esophagus Not involved 97 161 0.000**
Involved 44 8
Duodenum No 136 157 0.171
Yes 5 12
Signet ring cell carcinoma No 111 124 0.121
Partly 26 31
Mainly 4 14
T grade 3 136 72 0.000**
4 5 97
Borrmann type I + II 49 33 0.000**
III 86 28
IV 6 21
Grading Well and moderately differentiated 20 9 0.046*
Poorly differentiated 115 118
*p < 0.05, **p < 0.01
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cases by logistic regression. The results showed that
duodenal involvement was not related to incurable fac-
tors in multivariate analysis. However, cardia involve-
ment and Borrmann type were associated with T status
(Table 5).
Esophageal involvement and T grade were related to N
status in 310 cases in multivariate analysis by logistic re-
gression. The relationships of Borrmann type, esopha-
geal involvement, and T grade with N status were
analyzed in 223 cases by logistic regression. The results
showed that esophageal involvement and T grade were
associated with N status (Table 6).
Gastric body involvement, esophageal involvement,
and T grade were related to peritoneal metastasis in 310
cases in multivariate analysis by logistic regression. The
relationships of Borrmann type, gastric body involve-
ment, esophageal involvement, and T grade with
peritoneal metastasis were analyzed in 223 cases by lo-
gistic regression. The relationships of grading, gastric
body involvement, esophageal involvement, and T grade
with peritoneal metastasis were analyzed in 223 cases by
logistic regression. The results showed that gastric body
involvement, esophageal involvement, and T grade were
associated with peritoneal metastasis (Table 7).
Gastric antrum involvement was associated with dis-
tant metastasis in 310 cases in multivariate analysis by
logistic regression (Table 8).
Discussion
Although incurable gastrectomy may lead to a higher
quality of life and longer survival time in some reports
[7–10], the data are still disputable [11, 12]. Incurable
resection is associated with significant perioperative
morbidity and mortality as well as a limited overall
Table 2 Associations between the T status or N status and clinicopathological data
T status N status
No Yes p No Yes p
Gender Male 155 71 0.938 187 39 0.902
Female 58 26 70 14
Age <60 years 115 53 0.915 139 29 0.933
≥60 years 98 44 118 24
Cardia Not involved 142 87 0.000** 184 45 0.045
Involved 71 10 73 8
Gastric body Not involved 93 47 0.432 118 22 0.557
Involved 120 50 139 31
Gastric antrum Not involved 99 24 0.000** 106 17 0.214
Involved 114 73 151 36
Number of regions 1 127 63 0.657 159 31 0.326
2 80 32 90 22
3 6 2 8 0
Esophagus Not involved 166 92 0.000** 207 51 0.005
Involved 47 5 50 2
Duodenum No 206 87 0.012* 243 50 0.951
Yes 7 10 14 3
Signet ring cell carcinoma No 160 75 0.838 193 42 0.787
Partly 41 16 49 8
Mainly 12 6 15 3
T grade 3 208 0 0.000** 187 21 0.000
4 5 97 70 32
Borrmann type I + II 70 12 0.000** 76 6 0.002**
III 98 16 108 6
IV 12 15 20 7
Grading Well and moderately differentiated 24 5 0.275 26 3 0.404
Poorly differentiated 171 62 195 38
*p < 0.05, **p < 0.01
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survival; therefore, it should be performed judiciously
[11]. According to the National Comprehensive Cancer
Network (NCCN) guidelines version 1.2014, gastric re-
sections should be reserved for the palliation of symp-
toms (e.g., obstruction or uncontrollable bleeding) in
patients with incurable disease. In fact, in most cases,
the decision of palliative resection was made when the
tumor was found to be incurable by surgery in those pa-
tients scheduled for potentially curative resection. Over
the last few decades, surgery as the sole form of treat-
ment has been replaced by different forms of multidis-
ciplinary treatment for gastric cancer worldwide. The R0
resection rate has been significantly increased with neo-
adjuvant chemotherapy for gastric cancer [6].
Table 3 Associations between peritoneal metastasis or distant metastasis and clinicopathological data
Peritoneal metastasis Distant metastasis
No Yes χ2 p No Yes χ2 p
Gender Male 153 73 0.322 0.571 211 15 0.374 0.541
Female 54 30 80 4
Age <60 years 104 64 3.92 0.048 155 13 1.65 0.199
≥60 years 103 39 136 6
Cardia Not involved 148 81 1.818 0.178 214 15 0.27 0.603
Involved 59 22 77 4
Gastric body Not involved 108 32 12.371 0.000** 130 10 0.456 0.499
Involved 99 71 161 9
Gastric antrum Not involved 81 42 0.078 0.780 120 3 4.826 0.028*
Involved 126 61 171 16
Number of regions 1 132 58 7.045 0.030* 179 11 5.106 0.078
2 73 39 106 6
3 2 6 6 2
Esophagus Not involved 162 96 11.001 0.001** 240 18 1.921 0.166
Involved 45 7 51 1
Duodenum No 194 99 0.762 0.383 276 17 0.993 0.319
Yes 13 4 15 2
Signet ring cell carcinoma No 164 71 5.748 0.056 220 15 1.28 0.527
Partly 35 22 53 4
Mainly 8 10 18 0
T grade 3 153 55 13.111 0.000** 198 10 1.918 0.166
4 54 48 93 9
Borrmann type I + II 64 18 16.338 0.000** 77 5 1.488 0.475
III 96 18 111 3
IV 13 14 26 1
Grading Well and moderately differentiated 25 4 3.822 0.051 28 1 0.497 0.481
Poorly differentiated 160 73 217 16
*p < 0.05, **p < 0.01
Table 4 Multivariate analyses for curability
Curability
OR p aOR p
Esophageal Not involved 1 1
Involved 0.110 (0.005–0.242) 0.000 0.093 (0.032–0.266) 0.000**
T grade 3 1 1
4 36.644 (14.270–94.103) 0.000 39.957 (14.457–110.432) 0.000**
**p < 0.01
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However, the evaluation of curability for gastric cancer
is not completely accurate based on current imaging
technology. The current gold standard for T staging is
endoscopic ultrasonography (EUS), which has an accur-
acy between 65 and 92 % [13] and a sensitivity and spe-
cificity of 88 and 100 % for T1, 82 and 96 % for T2, 90
and 95 % for T3, and 99 and 97 % for T4, respectively
[14]. Multi-detector computed tomography (MDCT) for
T staging is less accurate than EUS, although the sensi-
tivity and specificity of serosa involvement are similar to
those of EUS [13, 14]. A meta-analysis involving nine
studies utilizing positron emission tomography (PET) to
evaluate gastric cancer reported that, despite the inabil-
ity to stage gastric cancer by tumor depth, PET has a
pooled primary tumor detection rate of 80 % in identify-
ing the existence of gastric cancer [15]. The sensitivity
and specificity for N staging using EUS are approxi-
mately 50–60 and 85–95 % [14], respectively, and
MDCT is not superior to EUS [13, 14]. PET can evaluate
node metabolism using the standardized uptake value
(SUV) in addition to acquiring the size of the lymph
nodes. However, the mean SUV noted for N staging can
also vary, with overall values ranging from 4.5 to 6.8 and
an overall accuracy ranging from 17.7 to 79.2 % [15].
The role of PET/CT is limited in T staging of primary
tumors due to its low spatial resolution, preventing the
evaluation of adjacent organ invasion [16]. For N sta-
ging, PET/CT is considered to have similar diagnostic
performance to that of contrast-enhanced CT [17].
CT was superior to PET in terms of sensitivity (p <
0.0001), and PET was superior to CT in terms of
specificity (p < 0.0001) and the positive predictive
value (PPV) (p = 0.05) [18].
For the preoperative diagnosis of peritoneal carcin-
omatosis (PC) of gastric cancer origin, useful imaging
techniques include ultrasonography, CT, magnetic res-
onance imaging, and 18F-fluorodeoxyglucose PET-CT
(FDG PET-CT), but all of these imaging techniques have
major limitations in diagnosing PC because of the low-
volume density of peritoneal nodules. Concerning PC of
gastric cancer origin, Yang et al. [19] reported a PET-CT
accuracy of 87 %, with a sensitivity and specificity of
72.7 and 93.6 %, respectively, which were better than
those for CT; however, for primary gastric cancer and
lymph node metastases, the accuracy for PET-CT is
54 %. CT is not accurate (8–17 % of sensitivity), particu-
larly for malignant granulations less than 5 mm in diam-
eter and small bowel nodulations. Due to the low
accuracy provided by the imaging, the main diagnostic
methods currently used to evaluate the peritoneal sur-
face are diagnostic laparoscopy or laparotomy and peri-
toneal cytological examination, which show greater
accuracies in diagnosing PC [20].
Therefore, the risk factors of surgery for incurable gas-
tric cancer need to be identified to evaluate curability.
However, no related research has been reported until
now. To our knowledge, the present study may be the
first to evaluate the risk factors for surgery of incurable
gastric cancer.
Our study found that esophageal involvement and T
grade were associated with curability. Cardia involve-
ment and Borrmann type were associated with T status.
Table 5 Multivariate analyses for the T status
T status
OR p aOR p
Cardia Not involved 1 1
Involved 0.263 (0.099–0.703) 0.008 0.275 (0.101–0.748) 0.011*
Borrmann type I + II 1 1
III 0.952 (0.424–2.138) 0.906 0.832 (0.363–1.908) 0.665
IV 2.700 (1.658–4.397) 0 2.767 (1.647–4.650) 0.000**
*p < 0.05, **p < 0.01
Table 6 Multivariate analyses for the N status
N status
OR p aOR p
Esophageal Not involved 1 1
Involved 0.162 (0.038–0.689) 0.014 0.220 (0.051–0.951) 0.043*
T grade 3 1 1
4 4.071 (2.201–7.531) 0 3.581 (1.921–6.676) 0.000**
*p < 0.05, **p < 0.01
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Esophageal involvement and T grade were associated
with N status. Gastric body involvement, esophageal in-
volvement, and T grade were associated with peritoneal
metastasis. Gastric antrum involvement was associated
with distant metastasis.
T grade is an important factor in tumor evaluation. Ac-
cording to the AJCC international staging standard, the T
grade can be classified as T1 to T4. Patients who present
with T4 gastric cancer (~20 % of the patient population)
will benefit from aggressive en bloc surgical resection and
should not be considered to have unresectable tumors
[21]. However, some T4 tumors were unresectable, form-
ing the T status of surgery for incurable gastric cancer.
The risk of regional nodal involvement increases with
deep penetration through the gastric wall [22], and the
nodal extension of the cancer occurs gradually, radiating
from the primary location via the lymphatic system [23,
24]. Nodal metastases are observed in 3–5 % of gastric
carcinomas limited to the mucosa. Of these nodal metas-
tases, 11–25 % extend to the submucosa, 50 % of the latter
reach the muscularis (T2), and 83 % of the latter extend to
the serosa (T3) [25, 26]. Our study revealed that T grade is
correlated with the N status and peritoneal dissemination
with surgery for incurable disease.
Esophageal involvement is a protective factor for sur-
gery for incurable disease and N status and peritoneal
dissemination with surgery for incurable disease. Cardia
involvement is a protective T factor for surgery for in-
curable disease likely because esophageal or cardia in-
volvement can cause digestive tract obstruction and can
be diagnosed earlier. Moreover, even if the tissues at the
gastroesophageal junction are invaded, they can be
resected easily.
The Borrmann type is divided into four types, and they
infiltrate in different ways. We discovered that the Borr-
mann type is related to the T status for surgery for in-
curable disease.
The penetration and dissemination of gastric cancer
cells into the peritoneal cavity is referred to as PC [27],
which is considered stage IV disease. Peritoneal dissem-
ination occurs more frequently than do hematogenous
metastases. The prognosis of gastric cancer patients with
PC is poor. Currently, in the intraoperative abdominal
examination, peritoneal seeding is found in 10–20 % of
patients scheduled for potentially curative resection and
in 40 % of those at stage II–III [28–30]. Cell distribution
into the peritoneal cavity is also dependent on physical
factors: the tumor primary site, effects of gravity, the
presence of fluids (e.g., ascites and mucus), and intrinsic
biological aggressiveness [31].
We discovered that gastric body involvement and T
grade were risk factors for peritoneal dissemination.
Peritoneal dissemination occurs only when the cancer
invades into the serosa, particularly when the gastric
body is involved. Esophageal involvement is a protective
factor for peritoneal dissemination with surgery for in-
curable disease. Esophageal involvement can cause di-
gestive tract obstruction and be diagnosed earlier.
Cancer more readily invades the tissue around the gas-
troesophageal junction than the peritoneal cavity, even if
the serosa has been invaded.
Our study revealed that gastric antrum involvement is
a risk factor for distant metastasis. The blood from the
gastric antrum flows to the portal vein through the right
gastric vein, possibly leading to liver metastasis.
We believe that the factors influencing surgery for in-
curable disease should be analyzed preoperatively. Re-
sectability should be evaluated according to these
influencing factors combined with imaging analysis. Lap-
aroscopic exploration is feasible when gastric cancer is
potentially incurable by surgery.
Conclusions
Esophageal involvement and the T grade were associated
with curability. Cardia involvement and Borrmann type
Table 7 Multivariate analyses for peritoneal metastasis
Peritoneal metastasis
OR p aOR p
Gastric body Not involved 1 1
Involved 2.420 (1.470–3.985) 0.001 2.576 (1.531–4.334) 0.000**
Esophageal Not involved 1 1
Involved 0.263 (0.114–0.605) 0.002 0.307 (0.130–0.728) 0.000**
T grade 3 1 1
4 2.473 (1.506–4.061) 0 2.348 (1.397–3.946) 0.000**
**p < 0.01
Table 8 Multivariate analyses for distant metastasis
Distant metastasis
OR p
Gastric antrum Not involved 1
Involved 3.743 (1.067–13.129) 0.039*
*p < 0.05
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were associated with the T status. Esophageal involve-
ment and the T grade were associated with the N status.
Gastric body involvement, esophageal involvement, and
the T grade were associated with peritoneal metastasis.
Gastric antrum involvement was associated with distant
metastasis. The factors influencing surgery for incurable
disease should be analyzed preoperatively. Resectability
should be evaluated according to these influencing fac-
tors combined with imaging analysis.
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